Zimmer Biomet (ZBH)
(Delayed Data from NYSE)
$111.29 USD
+0.65 (0.59%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $111.30 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$111.29 USD
+0.65 (0.59%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $111.30 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
Zacks News
Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, Zimmer markets products in more than 100 countries. In 2015, Zimmer Holdings, Inc. (the legacy company) acquired Biomet, Inc. to form a new consolidated company.
Here's Why You Should Retain Alcon (ALC) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Alcon (ALC) on the impressive performance of the Surgical and Vision Care segments.
The FOMC, ECB, and BoJ: Global Week Ahead
by John Blank
Key risk market moments in the Global Week Ahead? They center on major central banks, with the U.S. Fed, the European Central Bank (ECB) and the Bank of Japan (BoJ) meeting.
Here's Why Investors Should Retain ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about ResMed (RMD) backed by the continued demand for digital health solutions.
Syneos Health (SYNH) Sell-Off Appears Strategic Amid Margin Woes
by Zacks Equity Research
Syneos Health's (SYNH) purchase price represents a 24% premium to its unaffected closing stock price prior to the announcement. Margin pressure continues to weigh on the stock.
LabCorp (LH) Provides Update on Planned Spinoff of Fortrea
by Zacks Equity Research
After separation from LabCorp (LH), Fortrea is set to operate as a global contract research organization that offers comprehensive drug and medical device development services.
Here's Why Investors Should Retain Thermo Fisher (TMO) Stock
by Zacks Equity Research
Investors continue to be optimistic about Thermo Fisher's (TMO) continued strength across its end markets and the the execution of the growth strategy.
Here's Why You Should Invest in IDEXX (IDXX) Right Now
by Zacks Equity Research
Investors continue to be optimistic about IDEXX (IDXX) on the strength of the Companion Animal Group business.
Here's Why You Should Invest in Edward Lifesciences (EW) Now
by Zacks Equity Research
Investors continue to be optimistic about Edward Lifesciences (EW) on the strength of the Surgical Structural Heart business and the Critical Care segment.
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX) on the strength of the base business performance and its strategies to accelerate growth.
Zimmer (ZBH) Down 8.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Medtronic (MDT) on the robust performances of the Neurosurgery and Cardiovascular portfolios.
Down -8.05% in 4 Weeks, Here's Why You Should You Buy the Dip in Zimmer (ZBH)
by Zacks Equity Research
Zimmer (ZBH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Here's Why You Should Retain Integra (IART) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Integra Lifesciences (IART) based on the prospect of its CSS segment and ample liquidity to support M&A strategies.
ZBH vs. RMD: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ZBH vs. RMD: Which Stock Is the Better Value Option?
Here's Why You Should Retain Tandem Diabetes (TNDM) Now
by Zacks Equity Research
Investors continue to be optimistic about Tandem Diabetes (TNDM) based on the strong performance of the t:slim X2 insulin pump.
Here's Why Investors Should Hold Encompass Health (EHC) Now
by Zacks Equity Research
Encompass Health (EHC) remains well-poised for growth, attributable to expanding patient admissions, robust expansion endeavors and strong cash-generating abilities.
Here's Why You Should Retain Globus Medical (GMED) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Globus Medical (GMED) based on the strong performances across geographies and the pending NuVasive acquisition.
Here's Why You Should Retain Bruker (BRKR) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Bruker Corporation (BRKR) based on the strong performances of CALID and BioSpin Group and its raised 2023 outlook.
Boston Scientific (BSX) Gains From Acquisitions, New Launches
by Zacks Equity Research
Boston Scientific (BSX) remains excited about 2023 performance and expects to continue to outpace its peers within the EMEA market.
Abbott (ABT) Unveils Late-Breaking Data on Leadless Pacemaker
by Zacks Equity Research
Abbott (ABT) study analyzes primary safety and efficacy endpoints in the first 300 people enrolled across 55 centers in the United States, Canada and Europe.
Here's Why You Should Retain Chemed (CHE) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Chemed (CHE) on the strong performance of the VITAS Healthcare and Roto-Rooter segments.
Here's Why Investors Should Add Zimmer Biomet (ZBH) Now
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet (ZBH) on continued procedure recovery, solid execution and increasing traction around innovations.
Here's Why You Should Retain Insulet (PODD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Insulet (PODD) on the robust performance of Omnipod 5.
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
QIAGEN (QGEN) is likely to benefit from high organic growth across its non-COVID-19 product group and portfolio advancements, reflecting a positive share price movement.
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
by Zacks Equity Research
Myriad Genetics (MYGN) is likely to benefit from testing volumes across product segments and the latest partnerships, reflecting a positive share price movement.